NVCR(NovoCure Limited) 的财务报表:医疗保健,医疗器械。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $535.03M | $537.84M | $509.34M | $605.22M | $655.35M |
| 毛利润 | $420.15M | $422.97M | $381.06M | $468.04M | $488.47M |
| 营业利润 | −$44.33M | −$89.52M | −$232.87M | −$170.50M | −$153.80M |
| 净利润 | −$58.35M | −$92.53M | −$207.04M | −$168.63M | −$136.23M |
| 经营现金流 | $82.76M | $30.79M | −$73.34M | −$26.37M | −$49.03M |
| 自由现金流 | $58.59M | $9.43M | −$100.43M | −$69.22M | −$75.68M |
| 摊薄每股收益 | $-0.56 | $-0.88 | $-1.95 | $-1.56 | $-1.22 |